AbbVie (BUE:ABBV) Cyclically Adjusted FCF per Share: ARS1,666.76 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BUE:ABBV AbbVie Inc BUE:ABBV
62 GF Score
Price ARS40,320.00
GF Value ARS32,732.87
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is AbbVie Cyclically Adjusted FCF per Share?

AbbVie BUE:ABBV +1.20% 62 Cyclically Adjusted FCF per Share is ARS1,666.76 as of Mar. 2026. GuruFocus rates BUE:ABBV with a GF Score™ of 62/100 and a GF Value™ of ARS32,732.87 (Modestly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

AbbVie's adjusted free cash flow per share for the three months ended in Mar. 2026 was ARS2,809.101. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is ARS1,666.76 for the trailing ten years ended in Mar. 2026.

During the past 12 months, AbbVie's average Cyclically Adjusted FCF Growth Rate was 8.10% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 10.20% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 14.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of AbbVie was 17.70% per year. The lowest was 10.20% per year. And the median was 14.30% per year.

As of today (2026-07-20), AbbVie's current stock price is ARS40320.00. AbbVie's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was ARS1,666.76. AbbVie's Cyclically Adjusted Price-to-FCF of today is 24.19.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of AbbVie was 23.97. The lowest was 15.05. And the median was 18.61.


AbbVie  (BUE:ABBV) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

AbbVie's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=40320.00/1666.76
=24.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of AbbVie was 23.97. The lowest was 15.05. And the median was 18.61.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


AbbVie Cyclically Adjusted FCF per Share Related Terms


AbbVie Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for AbbVie's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AbbVie Cyclically Adjusted FCF per Share Chart

AbbVie Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 206.76 721.51 1,218.48 1,685.45

AbbVie Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,374.08 1,300.33 1,691.76 1,685.45 1,666.76

BUE:ABBV vs MRK, JNJ, AMGN: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - General subindustry, AbbVie's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AbbVie Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AbbVie's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where AbbVie's Cyclically Adjusted Price-to-FCF falls into.


BUE:ABBV
62GF Score
AbbVie Inc BUE:ABBV
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AbbVie Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AbbVie's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2809.101/330.2130*330.2130
=2,809.101

Current CPI (Mar. 2026) = 330.2130.

AbbVie Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 15.307 241.018 20.972
201609 12.197 241.428 16.682
201612 13.921 241.432 19.040
201703 19.303 243.801 26.145
201706 19.342 244.955 26.074
201709 34.380 246.819 45.996
201712 28.559 246.524 38.254
201803 31.890 249.554 42.197
201806 43.661 251.989 57.215
201809 103.037 252.439 134.782
201812 82.117 251.233 107.932
201903 76.704 254.202 99.640
201906 70.722 256.143 91.173
201909 165.968 256.759 213.448
201912 125.094 256.974 160.746
202003 154.337 258.115 197.447
202006 121.042 257.797 155.043
202009 234.898 260.280 298.011
202012 209.047 260.474 265.017
202103 237.963 264.877 296.660
202106 250.426 271.696 304.362
202109 424.685 274.310 511.234
202112 277.325 278.802 328.464
202203 286.607 287.504 329.183
202206 329.417 296.311 367.107
202209 580.914 296.808 646.294
202212 679.166 296.797 755.632
202303 446.935 301.836 488.953
202306 832.208 305.109 900.681
202309 1,453.350 307.789 1,559.234
202312 924.453 306.746 995.176
202403 1,828.030 312.332 1,932.685
202406 1,026.462 314.175 1,078.861
202409 2,788.205 315.301 2,920.072
202412 3,842.663 315.605 4,020.523
202503 842.241 319.799 869.668
202506 3,274.109 322.561 3,351.780
202509 5,091.014 324.800 5,175.859
202512 3,995.681 324.054 4,071.623
202603 2,809.101 330.213 2,809.101

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of ARS1,666.76 mean?
AbbVie (BUE:ABBV) has a Cyclically Adjusted FCF per Share of ARS1,666.76 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on AbbVie and its competitors.
Is AbbVie's Cyclically Adjusted FCF per Share too high?
AbbVie's current Cyclically Adjusted FCF per Share is ARS1,666.76. Overall, AbbVie has a GF Score™ of 62/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AbbVie's Cyclically Adjusted FCF per Share compare to MRK and JNJ?
AbbVie's Cyclically Adjusted FCF per Share of ARS1,666.76 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on AbbVie and its competitors. AbbVie's current Cyclically Adjusted FCF per Share is ARS1,666.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AbbVie stock overvalued right now?
Based on GuruFocus' analysis, AbbVie (BUE:ABBV) is currently considered Modestly Overvalued. The stock's GF Value™ is ARS32,732.87, compared to a current price of ARS40,320.00 — trading 23.2% above its estimated fair value. The current Cyclically Adjusted FCF per Share is ARS1,666.76. AbbVie's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For AbbVie (BUE:ABBV), the current Cyclically Adjusted FCF per Share is ARS1,666.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AbbVie (BUE:ABBV) Overvalued in 2026?

Based on GuruFocus' analysis, AbbVie stock appears to be overvalued. The current stock price of ARS40,320.00 is trading 23.2% above its estimated GF Value™ of ARS32,732.87. GuruFocus considers AbbVie to be Modestly Overvalued.

Key valuation signals for BUE:ABBV:

  • Cyclically Adjusted FCF per Share: ARS1,666.76
  • GF Value™: ARS32,732.87 vs. price of ARS40,320.00 (23.2% above fair value)
  • GF Score™: 62/100 with 4 warning signs

No single metric tells the full story. See the BUE:ABBV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AbbVie Business Description

Address 1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
62GF Score

Get the complete analysis for BUE:ABBV

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS40,320.00
Price
ARS32,732.87
GF Value